Phathom Pharmaceuticals | Evaluate

US FDA approval tracker: May

Go or no go? Lilly’s valuable diabetes contender

Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.

January 15, 2020

Last-ditch rally saves 2019 float tally

A stock market rebound created a strong finish for biopharma flotations in 2019, with four $100m-plus floats, led by Phathom Pharmaceuticals.